The first OSA drug treatment for obese adults offers new hope alongside diet and exercise therapy.
The FDA recently approved Zepbound (tirzepatide) in combination with a reduced-calorie diet and increased physical activity as a first-line drug treatment for moderate to severe obstructive sleep apnea (OSA) in obese adults. Zepbound reduces weight and improves OSA symptoms by targeting hormone receptors that suppress appetite.
“This approval marks the first drug treatment option for certain patients with obstructive sleep apnea,” said Sally Seymour, director of the Division of Pulmonology, Allergy, and Critical Care in the FDA’s Center for Drug Evaluation and Research. ” he said. This is a huge step forward for people with obstructive sleep apnea. ”
The approval was based on two placebo-controlled studies in 469 adults that demonstrated significant reductions in OSA events and body weight after 52 weeks of treatment. Lilly and Company received FDA approval for the drug, which received Fast Track, Priority Review, and Breakthrough Therapy designations.
Follow the Lord’s guidance and pray with us…
- Director Seymour seeks divine guidance as he oversees the pulmonology, allergy, and critical care departments at the Center for Pharmaceutical Evaluation and Research.
- FDA Director General Caliph will be guided by the Lord to direct the FDA approval process.
source: food and drug administration
Recent prayer updates
